Cáncer de piel: Una realidad cotidianamente ignorada.

Contenido principal del artículo

Autores

María Lucía Iregui Piñeros
Jaime Ronderos Osorio

Palabras clave:

Detalles del artículo

Referencias

(1) Cancer incidence in five continents. IARC Sci Publ. 2008; IX(160):1-837.

(2) Diepgen TL, Mahler V. The epidemiology of skin cancer.
Br J Dermatol. 2002; 146 Suppl 61:1-6.

(3) Sánchez G, Nova J, De la Hoz F, Castañeda C. Incidencia de cáncer de piel en Colombia. Años 2003-2007. Piel. 2011; 26 (4):171-7.

(4) Garavís JL. Precáncer y cáncer cutáneo en AP. En: Semergen 2003; 29(7); 360-367. [Internet] 2003 [citado 11 septiembre 2014]. Disponible en: http://www.sciencedirect.com/science.

(5) Fundación Universitaria de Ciencias de la Salud, Instituto Nacional de Cancerología, Centro Dermatológico Federico Lleras Acosta y Asociación Colombiana de Dermatología y Cirugía Dermatológica -ASOCOLDERMA. Guía de práctica clínica con evaluación económica para la prevención, diagnóstico, tratamiento y seguimiento del cáncer de piel no melanoma: Guía para pacientes, padres y cuidadores.

(6) Instituto Nacional de Cancerología ESE, Ministerio de Salud y Protección Social. Anuario Estadístico 2011. Bogotá́: Milenio Editores. 2014; 9:28.

(7) Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Primera edición. Bogotá́. D.C. Instituto Nacional de Cancerología. 2015; 1:148.

(8) International Agency Research on Cancer. CI5 I-X Cancer incidence in five continents volume X (2003-2007). [on line] 2015 [citado 27 febrero 2015] disponible en: http://ci5.iarc.fr/CI5I-X

(9) International Agency for Research on Cancer–OMS. GLOBOCAN 2012 Estimated cancer incidence mortality and prevalence Worldwide in 2012. World. Population Facts Sheets. [On line] 2012 [cited 10 September 2014] availablein:http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

(10) Surveillance, Epidemiology and End Results Program (SEER). National Institutes of Health. SEER stat fact sheets: melanoma of skin. [On line] 2011 [citado 10 septiembre 2014]. Disponible en: http://www.seer.cancer.gov/ statfacts/html/melan.html

(11) McKenzie RL, Aucamp PJ, Bais AF, Bjorn LO, Ilyas M. Changes in biologically- active ultraviolet radiation reaching the Earth ́s surface. Photochemical y photobiological sciences. 2007; 6(3): 218-231. Pubmed PMID: 17344959. Citado por: Sánchez Guillermo. Cáncer de piel no melanoma: riesgos e itinerarios. Bogotá: Universidad Nacional de Colombia. 2013; p. 37.

(12) Bulliard JL, Cox B, Elwood JM. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Causes Control. 1994; 5: 234–240. Citado por: S Wu, J Han, R.A Vleugels, R Puett, F Laden, DJ Hunter and Qureshi. Cumulative ultaviolet radiation flux in adulthood and risk of incident skin cancers in women. British Journal of Cancer [on line] 2014 March [cited 2014 Oct 30]; 110: 1855-1861. Available from: http://www. nature.com/bjc/journal/v110/n7/full/bjc201443a.html. p.1854.

(13) Almahroos M, Kurban AK (2004). Ultraviolet carcinogenesis in nonmelanoma skin cancer. Part I: incidence rates in relation to geographic locations and in migrant populations. Skinmed 3:29–35, quiz35-36. Citado por: S Wu, J Han, R.A Vleugels, R Puett, F Laden, DJ Hunter and Qureshi. Cumulative ultaviolet radiation flux in adulthood and risk of incident skin cancers in women. British Journal of Cancer [on line] 2014 March [cited 2014 Oct 30]; 110: 1855-1861. Available from:http://www.nature.com/bjc/journal/v110/n7/full/bjc201443a.html. p.1854.

(14) Qureshi AA, Laden F, Colditz GA, Hunter DJ (2008). Geographic variation and risk of skin cancer in US women. Diferences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med [on line] 2008 [cited 2014 Oct 30]; 168: 501–507. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/1833229.

(15) Suzuki T, Ueda M, Ogata K, Horikoshi T, Munakata N, Ichihashi M. Doses of solar ultraviolet radiation correlate with skin cancer rates in Japan. Kobe J Med Sci. 1996; 42: 375–388. Citado por: S Wu, J Han, R.A Vleugels, R Puett, F Laden, DJ Hunter and Qureshi. Cumulative ultaviolet radiation flux in adulthood and risk of incident skin cancers in women. British Journal of Cancer [on line] 2014 March [cited 2014 Oct 30]; 110: 1855-1861. Available from: http://www. nature.com/bjc/journal/v110/n7/full/bjc201443a.html. p.1854

(16) Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer–the role of sunlight. Adv Exp Med Biol. 2008; 624: 89–103. Citado por: S Wu, J Han, R.A Vleugels, R Puett, F Laden, DJ Hunter and Qureshi. Cumulative ultaviolet radiation flux in adulthood and risk of incident skin cancers in women. British Journal of Cancer [on line] 2014 March [cited 2014 Oct 30]; 110: 1855-1861. Available from: http://www.nature.com/bjc/journal/v110/ n7/full/bjc201443a.html. p.1854.

(17) Pozzobón F, Acosta A, Carreño A, Fierro E. Características del melanoma cutáneo primario en el Instituto Nacional de Cancerología 2006-2010. [en línea] En: Rev Col Cancerol. 2013; 17(3):111-118. [citado el 14 de enero de 2015] disponible en: http://zl.elsevier.es. p.114.

(18) Dong C, Hemminki K. Int J Cancer. 2001; Jul 15; 93(2):155-61. Second primary neoplasm in 633.964 cancer patients in Sweden, 1958-1996. Citado por: Guianeya S, Lombardo K y Rodríguez R. Tumores múltiples análisis de 25 casos. En: Salud Militar. 2006; 28(1):73-80.

(19) Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2013; 49(10):2365-75.

(20) Van der Leest RJ, Flohil SC, Arends LR, de Vries E, Nijsten T. El riesgo de malignidad cutánea posterior en pacientes con melanoma antes: una revisión sistemática y metanálisis. J Eur Acad Dermatol Venereol. 2014; diciembre 10.

(21) Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;(1):CD003412.

(22) Acosta A, Ramírez A, Rueda X. Carcinoma escamocelular. En: Atlas Dermatología Oncológica. Instituto Nacional de Cancerología. CD multimedia. Bogotá́: 2006.

(23) Peñaranda E, Rolon M, Acosta AE, Rueda X. Concordancia entre biopsia incisional y pieza quirúrgica en los subtipos histológicos del carcinoma basocelular. Protocolos investigación I.N.C. 2001.

(24) Gallagher RP, Hill GB, Bajdik CD, Fincham S, Coldman AJ, Threlfall WJ, et al. Sunlight exposure, pigmentary factors and risk of non-melanocytic skin cancer. Basal cell carcinoma. Arch Derm. 1995; 131: 157-163.

(25) Guidelines Index Basal Celland Squamous Cell TOCStaging, MS, Clinical Practice Guidelines in Oncology – v.2.2005. National Comprehensive Cancer Network.

(26) Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J-Dermatol-Surg-Oncol. 1992; 18: 471-6.

(27) Rubin A, Chen E, Ratner D. Currentconcepts Basalcellcarcinoma. N Engl J Med. 2005; 353: 2262-9.

(28) Miller SJ. Basal Cell Carcinoma -Risk Factors, in: Miller S, Maloney M et al. Cutaneos Oncology. England: Blackwell Science. 1998; 614-8.

(29) Acosta A, Rueda X. Indicaciones terapéuticas del carcinoma basocelular y escamocelular según sus factores de riesgo. En Coiffman P, et al. Cirugía plástica, reconstructiva y estética de cabeza y cuello. Tercera edición, Tomo 2. Amolca; 2007; 965-84.

(30) Mikhail GR, Nims LP, Kelly AP Jr, Ditmars DM Jr, Eyler WR. Metastatic basal cell carcinoma. Review, pathogenesis and report of two cases. Arch Derm. 1977; 113:1261-1269.

(31) Epstein E. Fluorouracil paste treatment of the basal cell carcinoma. Arch Derm. 1985; 121: 207-213.

(32) Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol.1981; 4: 633-49.

(33) Bergstresser P, Halprin K. Multiple sequential skin cancer. The risk of skin cancer in patients with previous skin cancer. Arch Derm. 1975; 111: 995-6.

(34) Epstein E. Value of follow-up after treatment of basal cell carcinoma. Arch Derm. 1973; 106: 798-800.

(35) Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making. 1994; 14(1):52-8.

(36) Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Airs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115(11):2523-30.

(37) Lansbury L, Leonardi J, Perkins W, Goodacre T, Tweed JA, Bath FJ. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010; (4):CD007869.

(38) NCCN. National Comprehensive Cancer Network. Basal Cell and Squamous Cell Skin Cancers. NCCN Guidelines. 2014; 2:1- 48. Disponible en: www.nccn.com.

(39) Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012; 12:CD004415.

(40) López JM, Cebrián JL, Palacios E, Macarrón J, Pingarrón L, Demaría G et al. Carcinoma cutáneo de células de Merkel: Presentación de un caso y revisión de la literatura. Rev Esp Cirug Oral y Maxilofac [revista en la Internet]. 2008 Feb [citado 2015 Feb 26]; 30(1): 29-34. Disponible en:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130- 05582008000100004&lng=es

(41) Goessling W. Merkel cell carcinoma. J Clin Oncol 2002; 20:588-598. Citado por: López JM, Cebrián JL, Palacios E, Macarrón J, Pingarrón L, Demaría G et al. Carcinoma cutáneo de células de Merkel: Presentación de un caso y revisión de la literatura. Rev Esp Cirug Oral y Maxilofac [revista en la Internet]. 2008 Feb [citado 2015 Feb 26]; 30(1): 29-34. Disponible en:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130- 05582008000100004&lng=es

(42) Biblioteca Nacional de Medicina de EEUU. Sarkoma de Kaposi. [en línea] 2012 [citado 27 febrero 2015]. Disponible en: http://www.nlm.nih.gov/medlineplus/ spanish/ency/article/000661.htm

(43) Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophtalmology [internet]. 2001 April [citado 2015 Feb 27] 108: 1877-1883. Disponible en: http://www.aaojournal.org/article/ S0161-6420%2801%2900719-9/pdf

(44) Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 2004. [Internet]. 2004 Jul [citado 2015 Feb 27]; 111: 2151-2157. Disponible en: http://www.sciencedirect.com/science/article/pii/S0161642004012928

(45) Ni C, Searl S, Kuo PK. Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin 1982; 22: 23-61. Iglesias I, Troyano J, Díaz D, Genol I. Citado por: Carcinoma de glándulas sebáceas: presentación de dos casos clínicos. Arch Soc Esp O almol [revista en la Internet]. 2008 Jul [citado 2015 Feb 27]; 83(7): 445-448. Disponible en: http://scielo.isciii.es/scielo. php?script=sci_arttext&pid=S0365-66912008000700011&lng=es

(46) Mohr P et al. Staging of cutaneous melanoma. Annals of Onc. 20 (supplement 6): 14-21, 2009.

(47) Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 221:566-9, 1995.

(48) Weiss, M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of Follow-up Tests for Detecting Recurrent Disease in Patients With Malignant Melanomas. JAMA 274:1703-1705, 1995.

(49) Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Evidence and interdisciplinary consense-based. German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007 Dec; 17(6):393-9.

(50) Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82.

(51) The NCCN Clinical Practice Guidelines in Oncology TM Melanoma (Version 2.2011). Disponible en: www.nccn.org.

(52) Nguyen y Jaeyoung Yoon. Carcinoma epidermoide. En: Rigel D, Friedman R, Dzubow L, Reintgen D, Bystryn JC and Marks R. Cáncer de piel. Madrid: Elsevier; 2006, p. 133 v.

(53) Melanoma. http://www.seom.org/es/informacion-sobre-el-cancer/info-tipos-cancer/melanoma?start=6#sthash.CO8BFszn.dpuf

(54) Carter R, Marks R, Hill D. Could a national skin cancer primary prevention campaign in Australia be worthwhile?: An economic perspective. Health Promotion International. 1999; 14(1):73-82.

(55) Gordon LG, Scuffam PA, van der Pols JC, McBride P, Williams GM, Green AC. Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol. 2009; 129(12):2766-71.

(56) Hirst NG, Gordon LG, Scuffam PA, Green AC. Lifetime cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use. Value Health. 2012; 15(2):261-8.

(57) Shih ST, Carter R, Sinclair C, Mihalopoulos C, Vos T. Economic evaluation of skin cancer prevention in Australia. Prev Med. 2009; 49(5):449-53.

(58) Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 2003; 149(66):31-3.

(59) Mancebo SE, Hu JY, Wang SQ. Sunscreens: A Review of Health Benefits, Regulations, and Controversies. Dermatol Clin. 2014; 32(3):427-38.

(60) Ministerio de Salud y Protección Social. Instituto Nacional de Cancerología. Anuario Estadístico 2010. Vol. 8. Bogotá: Buenos y Creativos. 2012.

(61) Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making. 1994; 14(1):52-8.

(62) Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans A airs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115(11):2523-30.

(63) Lansbury L, Leonardi J, Perkins W, Goodacre T, Tweed JA, Bath FJ. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010; (4):CD007869.

(64) NCCN. National Comprehensive Cancer Network. Basal Cell and Squamous Cell Skin Cancers. NCCN Guidelines. 2014; 2:1-48. Disponible en: URL: www.nccn.com

(65) Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013; 133(5):1188-96.

(66) Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet. 2004; 364(9447):1766-72.

(67) Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012; 12:CD004415.

(68) Briggs AH. Handling uncertainty in cost-e ectiveness models. Pharmacoeconomics. 2000; 17(5):479-500.

Descargas

La descarga de datos todavía no está disponible.